Article and Video CATEGORIES
Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
Article
Da click aquí para más información y para registrarte ahora
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on